Synergistic effect of bromocriptine and tumor necrosis factor-α on reversing hepatocellular carcinoma multidrug resistance in nude mouse MDR1 model of liver neoplasm

Table 1 MDR1, LRP primers

Gene	Quantification method	Sequence (5’–3’)	Size (bp)
MDR1	Forward primer	CATTGGTGTGGTGAGTCAGG	176
	Reverse primer	CTCTCTCTCCAACCAGGGTG
LRP	Forward primer	TAAGGGCTTCCAGCACCAAC	237
	Reverse primer	GGAGTTCTCGCTTCTCGTCC
TNF-α	Forward primer	GCGGATTCATGAGCACTGAAAGCATGATCC	725
	Reverse primer	CCCAAGCTTTCACAGGGCAATGATCCCAAAG
β -actin	Forward primer	GTGCGTGACATTAAGGAG	530
	Reverse primer	CTAAGTCATAGTCCGCCT

Table 2 Volume and size of orthotopic tumor tissues (mean±SD)

Groups	Mice and incidenceof tumor, n (%)	Volume(cm3)	Rate of volumeinhibition (%)	Weight(g)	Rate of weightinhibition (%)
HepG2			57		54
Experiment	8 (100)	1.25 ± 0.13		0.72 ± 0.12
Control	8 (100)	2.92 ± 0.21		1.55 ± 0.17
ADM			14		18
Experiment	8 (100)	2.03 ± 0.11		1.22 ± 0.11
Control	8 (100)	2.37 ± 0.18		1.48 ± 0.21
TNF			58a		57
Experiment	8 (100)	0.67 ± 0.22		0.45 ± 0.16
Control	8 (100)	1.37 ± 0.18		0.93 ± 0.18
BCT			66c		67
Experiment	8 (100)	0.49 ± 0.17b		0.29 ± 0.21
Control	8 (100)	1.45 ± 0.26		0.88 ± 0.17

^aP>0.05 vs HepG₂ group, χ² = 4.32;

^bP<0.01 vs ADM group, t = 2.38;

^cP<0.05 vs HepG₂ group, χ² = 2.49.

Table 3 mRNA level of MDR-associated genes in response to TNF-α gene induction (mean±SD)

Groups	MDR1mRNA	LRPmRNA
BCT	0.21 ± 0.02ac	0.17 ± 0.04
TNF	0.15 ± 0.03ac	0.15 ± 0.01
ADM	0.89 ± 0.15	0.83 ± 0.12
HepG2	0.13 ± 0.02c	0.11 ± 0.01

^aP>0.05 vs HepG₂ group;

^cP<0.05 vs ADM group.

Table 4 Apoptosis index of each kind of tumors (mean±SD)

Group	Mice (no)	Experimental (indexof apoptosis)
BCT	8	30.5 ± 4.2abc
TNF	8	21.9 ± 2.1bc
ADM	8	2.3 ± 1.8
HepG2	8	23.7 ± 2.9

^aP<0.05 vs TNF group;

^bP<0.01 vs ADM group;

^cP>0.05 vs HepG₂ group.